Japanese drugmaker wins fees in cancer drug feud
Japan’s Daiichi Sankyo says it has been awarded almost US$46 million in fees and costs after prevailing in an ICDR arbitration with US biotech group Seagen over rights to technology used in cancer medicines.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.